FAST NEWS: Beigene stock falls after Novartis terminates partnership
The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Tuesday that Novartis (NOVN.SWX) will relinquish its rights to co-develop, produce and commercialize BeiGene’s esophagus cancer drug tislelizumab. Looking up: Novartis will provide…
BGNE.US
6160.HK
Sales success comes with side effects for drug maker BeiGene
The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs Key Takeaways: Global sales of BeiGene's anti-tumor drug zanubrutinib…
BGNE.US
6160.HK
Laekna IPO hopes to hitch a ride on Novartis ties
The producer of drugs licensed from third parties is banking on ties to the Swiss drug maker, as one of its key products nears the regulatory finish line Key Takeaways:…
FAST NEWS: Antengene Appoints New Chief Medical Officer
The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) said on Wednesday Kevin Patrick Lynch has resigned as an executive director and chief medical officer (CMO) to retire, but will remain…
With Zero Revenue, Laekna Plays Chicken-And-Egg Game With Investors
The biotechnology company, which is facing ballooning losses without any revenue like many of its peers, has filed for an IPO in Hong Kong (more…)
FAST NEWS: Biotech Startup Sciwind Lands $70 Million in New Funding
The latest: Biotech startup Hangzhou Sciwind Biosciences Co. Ltd. announced it has closed its third funding round, raising 450 million yuan ($70 million). New backers in the latest round included…
